Genmab advances on earnings strength and pipeline while lower valuation opens upside
Genmab delivered better-than-expected Q3 results, confirmed its 2025 Guidance and continued to diversify beyond Darzalex with growing royalties, co-owned assets and a robust late-stage pipeline. The planned Merus deal and a markedly lower valuation strengthen the medium-term equity story.
Published on 11/07/2025
at 08:31 pm IST - Modified on 11/07/2025
at 07:54 pm IST
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (80.6%);
- income from research and development (9.3%);
- other (10.1%): primarily income from partnership agreement.
At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
This Alphavalue article, the European leader in independent research, is only available to subscribers .
